Work

Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex

Year: 2013

Type: article

Abstract: Meeting abstracts The results of multiple IL-2 clinical trials (using a range of doses) have shown similar trends, in which IL-2 immunotherapy leads to an objective response in 15-20% of patients and complete response in 5-10%. Importantly, the majority (> 80%) of patients with a complete response

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-1-s1-p266

Authors: Andrew Zloza, Joseph R Broucek, Erica J Huelsmann, Tasha Hughes, Howard L Kaufman

Institution: Rush University Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490